This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Boston biotech Kojin Therapeutics is closing its doors, citing four funding chal...
The company’s randomized clinical trial, published in Nature Medicine, tested th...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Bambusa Therapeutics has raised about $90 million to build out a pipeline of nex...
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts ha...
After its depression candidate failed a phase 3 trial and disappointed analysts,...
Corbus Pharmaceuticals has posted the first Western clinical data on its would-b...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the F...
Otsuka has broken up with a clutch of clinical cancer candidates. The Japanese d...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial,...
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversit...
As an initial demonstration, researchers tasked their RFdiffusion AI model with ...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biote...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Amgen and Ideaya Biosciences are winding down their cancer combination study, cl...
Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in a...
Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s see...
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vacc...
Newleos Therapeutics is making its debut with $93.5 million aimed at developing ...
Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis...
Less than a month after researchers unveiled that a “ticking DNA clock” is behin...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the ne...